Pensionfund Sabic Makes New $3.05 Million Investment in Merck & Co., Inc. $MRK

Pensionfund Sabic purchased a new stake in shares of Merck & Co., Inc. (NYSE:MRK) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 29,000 shares of the company’s stock, valued at approximately $3,053,000.

Several other hedge funds and other institutional investors have also recently made changes to their positions in MRK. Darwin Wealth Management LLC boosted its holdings in shares of Merck & Co., Inc. by 237.4% in the third quarter. Darwin Wealth Management LLC now owns 307 shares of the company’s stock worth $26,000 after buying an additional 216 shares during the last quarter. Kilter Group LLC purchased a new stake in Merck & Co., Inc. during the second quarter valued at approximately $27,000. Bare Financial Services Inc increased its holdings in Merck & Co., Inc. by 51.9% during the second quarter. Bare Financial Services Inc now owns 366 shares of the company’s stock valued at $29,000 after buying an additional 125 shares during the last quarter. Barnes Dennig Private Wealth Management LLC raised its position in Merck & Co., Inc. by 302.3% in the third quarter. Barnes Dennig Private Wealth Management LLC now owns 354 shares of the company’s stock worth $30,000 after acquiring an additional 266 shares during the period. Finally, Evolution Wealth Management Inc. bought a new position in Merck & Co., Inc. in the second quarter worth approximately $31,000. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Insider Transactions at Merck & Co., Inc.

In other Merck & Co., Inc. news, CFO Caroline Litchfield sold 41,997 shares of Merck & Co., Inc. stock in a transaction on Wednesday, February 4th. The shares were sold at an average price of $119.61, for a total value of $5,023,261.17. Following the sale, the chief financial officer directly owned 90,192 shares in the company, valued at approximately $10,787,865.12. The trade was a 31.77% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Jennifer Zachary sold 121,573 shares of Merck & Co., Inc. stock in a transaction on Monday, February 9th. The shares were sold at an average price of $119.15, for a total transaction of $14,485,422.95. Following the completion of the sale, the executive vice president owned 68,916 shares in the company, valued at approximately $8,211,341.40. This represents a 63.82% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 320,176 shares of company stock valued at $38,281,735. 0.09% of the stock is owned by corporate insiders.

Merck & Co., Inc. Stock Performance

NYSE:MRK opened at $116.26 on Wednesday. The company has a current ratio of 1.54, a quick ratio of 1.30 and a debt-to-equity ratio of 0.89. Merck & Co., Inc. has a 12-month low of $73.31 and a 12-month high of $125.14. The stock has a 50-day moving average price of $116.10 and a 200 day moving average price of $101.32. The stock has a market capitalization of $287.43 billion, a P/E ratio of 15.97, a P/E/G ratio of 2.24 and a beta of 0.27.

Merck & Co., Inc. (NYSE:MRK) last issued its earnings results on Tuesday, February 3rd. The company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.01 by $0.03. Merck & Co., Inc. had a return on equity of 44.57% and a net margin of 28.08%.The company had revenue of $16.40 billion for the quarter, compared to the consensus estimate of $16.19 billion. During the same quarter last year, the company earned $1.72 EPS. The firm’s quarterly revenue was up 5.0% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. Equities research analysts forecast that Merck & Co., Inc. will post 9.01 EPS for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 7th. Stockholders of record on Monday, March 16th will be given a dividend of $0.85 per share. The ex-dividend date is Monday, March 16th. This represents a $3.40 annualized dividend and a dividend yield of 2.9%. Merck & Co., Inc.’s dividend payout ratio (DPR) is presently 46.70%.

Key Stories Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Signed a multi?year research collaboration with Quotient Therapeutics to discover IBD drug targets using Quotient’s somatic genomics platform; the deal includes an upfront payment and a milestone structure worth up to $2.2 billion, giving Merck access to novel target?finding technology that could expand its inflammation franchise and long?term growth prospects. Quotient Therapeutics Announces Collaboration with Merck to Discover Novel Drug Targets in Inflammatory Bowel Disease Using Somatic Genomics Platform Technology
• Positive Sentiment: Analyst/press writeups note the strategic value of the Quotient tie?up and discuss valuation upside if the somatic?genomics approach yields actionable targets—this coverage can help re?rate MRK on pipeline optionality and future royalties/booked milestones. Assessing Merck (MRK) Valuation After New IBD Genetics Collaboration With Quotient Therapeutics
• Positive Sentiment: Commercial progress for WINREVAIR® (sotatercept): several Canadian jurisdictions have added the product to public formularies following a pCPA agreement, improving access and supporting upside in pulmonary arterial hypertension revenue. Greater public coverage reduces uptake risk and supports revenue visibility in Canada. New Public Listings for Canadians Living with Pulmonary Arterial Hypertension
• Positive Sentiment: Merck’s most recent quarterly results (reported Feb 3) beat EPS and revenue estimates and management provided FY2026 EPS guidance—this fundamental backdrop (solid margins, strong ROE, and guidance) underpins investor confidence alongside the new deals. (Company filings and earnings release)
• Neutral Sentiment: Market commentary and scans flagged MRK among S&P 500 large caps to watch and noted recent outperformance versus the index—these are market?flow and sentiment items that can amplify moves but don’t change fundamentals by themselves. 1 S&P 500 Stock to Target This Week and 2 We Ignore
• Neutral Sentiment: Price recaps and short pieces (Zacks/Yahoo) note recent gains—useful for tracking momentum but not new catalysts. Merck (MRK) Exceeds Market Returns: Some Facts to Consider

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on MRK shares. TD Cowen boosted their price objective on shares of Merck & Co., Inc. from $100.00 to $120.00 and gave the company a “hold” rating in a research report on Tuesday, January 20th. Wolfe Research raised Merck & Co., Inc. from a “peer perform” rating to an “outperform” rating and set a $135.00 target price on the stock in a report on Thursday, January 8th. Morgan Stanley lifted their target price on Merck & Co., Inc. from $100.00 to $102.00 and gave the company an “equal weight” rating in a research report on Friday, December 12th. Deutsche Bank Aktiengesellschaft raised Merck & Co., Inc. from a “hold” rating to a “buy” rating and set a $150.00 price target for the company in a report on Friday, February 13th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Merck & Co., Inc. in a research report on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and seven have assigned a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $127.13.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.